An acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancer

We report a HER2(T798I) gatekeeper mutation in a patient with HER2(L869R)-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2(L869R) is a neratinib-sensitive, gain-of-function mutation that upon dimerization with mutant HER3(E928G), also present in the...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Hanker, Ariella B., Brewer, Monica Red, Sheehan, Jonathan H., Koch, James P., Sliwoski, Gregory R., Nagy, Rebecca, Lanman, Richard, Berger, Michael F., Hyman, David M., Solit, David B., He, Jie, Miller, Vincent, Cutler, Richard E., Lalani, Alshad S., Cross, Darren, Lovly, Christine M., Meiler, Jens, Arteaga, Carlos L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457707/
https://ncbi.nlm.nih.gov/pubmed/28274957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1431
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi